Bioanalytical Excellence Upheld - Unannounced US FDA inspection concludes with Zero 483s - Lambda CRO
Bioanalytical Excellence Upheld – Unannounced US FDA inspection concludes with Zero 483s
NEWS
Lambda Clears 4 Back-to-Back US FDA PV Inspections in 12 Months Without 483s
Lambda Successfully Completes US FDA Pharmacovigilance Inspection with Zero 483s – 4th Consecutive in One Year
NEWS
Clinical Research Update – June 2025
Clinical Research Updates provides key insights into the latest developments, trends, and breakthroughs shaping the clinical research landscape. Stay informed with concise summaries of regulatory updates, industry collaborations, and advancements…
Full-Service CRO Integrated Solutions That Accelerate Drug Development
Full-Service CRO | End-to-End Expertise for Every Phase of Clinical Development
In today’s complex drug development landscape, successful execution requires more than isolated services. It demands a CRO partner that understands your science, aligns with your goals, and delivers across every…
Clinical Research Update – May 2025
Clinical Research Updates provides key insights into the latest developments, trends, and breakthroughs shaping the clinical research landscape. Stay informed with concise summaries of regulatory updates, industry collaborations, and advancements…
Bioequivalence Study of Semaglutide Injection (GLP-1 analogue)
Insights: Bioequivalence Study of Semaglutide Injection
Bioequivalence Study of Semaglutide Injection (GLP-1 analogue)
Study Insights: Bioequivalence Study of Semaglutide Injection 1.34 mg/ml (2 mg/1.5 mL)
Blog
Ovarian Cancer Clinical Trials CRO India USA
Ovarian Cancer Clinical Trials – Advancing Research Through Patient-Focused Approaches
Blog
US FDA Inspection Success - NO FORM 483 - Lambda CRO
Lambda Ahmedabad Successfully Completes USFDA Inspection without any 483 Observations
NEWS
Lambda CRO - End-to-end Biosimilar Development and Clinical Trials Expertise
End-to-end Biosimilar Development and Clinical Trials Expertise